Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. engages in the research and development, manufacture, and commercialization of novel drugs. The company is headquartered in Chengdu, Sichuan and currently employs 1,870 full-time employees. The company went IPO on 2023-07-11. The firm is mainly engaged in the research and development, manufacturing and commercialization of novel drugs in oncology, immunology and other therapeutic areas. The firm's products are antibody drug conjugates (ADCs) SKB264, A166 and others. The firm's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, gastrointestinal cancer and other diseases.
06990.HK stock price ended at $469.2 on 星期四, after dropping 0.97%
On the latest trading day Jan 08, 2026, the stock price of 06990.HK fell by 0.97%, dropping from $473.80 to $469.20. During the session, the stock saw a volatility of 5.99%, with prices oscillating between a daily low of $457.60 and a high of $485.00. On the latest trading day, the trading volume for 06990.HK rose by 1.4M shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 2.7M shares were traded, with a market value of approximately $76.3B.